CoChat

Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma

Open access
Choy, Edwin, Flamand, Yael, Balasubramanian, Sriram, Butrynski, James E., Harmon, David C., George, Suzanne, Cote, Gregory M., Wagner, Andrew J., Morgan, Jeffrey A., Sirisawad, Mint, Mani, Chitra, Hornicek, Francis J., Duan, Zhenfeng, Demetri, George D. · 2015 · Cancer
Cited by 62

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

BACKGROUND: It has been demonstrated that several inhibitors of histone deacetylase (HDAC) can enhance chemotherapy‐induced apoptosis and reduce sarcoma tumor volume in preclinical models. The authors sought to determine the maximum tolerated dose, pharmacokinetics/pharmacodynamics, safety, and toxicity of the HDAC inhibitor abexinostat (PCI‐24781) when administered with doxorubicin to patients with metastatic sarcomas. METHODS: Participants were enrolled in a standard, phase 1, 3 + 3, dose‐escalation study design. Abexinostat was administered on days 1 through 5 with 75 mg/m 2 of doxorubicin administered on day 4 of every 21‐day cycle until patients developed disease progression or drug intolerance or reached a cumulative lifetime doxorubicin dose of 450 mg/m 2. Granulocyte‐colony–stimulating factor (G‐CSF) support was provided at physician discretion on arm A and was provided to all participants in arm B. From 3 to 6 participants initially received abexinostat 30 mg/m 2 twice daily, and subsequent cohorts were administered doses of 15 mg/m 2, 45 mg/m 2, or 60 mg/m 2 twice daily. All patients without progressive disease after receiving a cumulative lifetime doxorubicin dose of 450 mg/m 2 were given the option to continue with abexinostat as a single agent until they developed disease progression. RESULTS: In total, 22 participants (10 who had previously experienced tumor growth after doxorubicin therapy) were enrolled (6 in arm A, 14 in arm B), 20 were evaluable for dose‐limiting toxicity (DLT), and 17 were evaluable for radiologic response. In arm A, participants received abexinostat 15 mg/m 2 or 30 mg/m 2 twice daily. DLTs of grade 3 and 4 neutropenia were observed in 2 of 3 participants who received abexinostat 30 mg/m 2 twice daily. Neither of those patients received G‐CSF prophylaxis. In arm B, participants received abexinostat at doses of 30 mg/m 2, 45 mg/m 2, or 60 mg/m 2 twice daily, all with mandated G‐CSF support. Two DLTs were observed at the 60 mg/m 2 twice‐daily dose (grade 3 infection, grade 4 thrombocytopenia). The pharmacokinetics of abexinostat were not affected by doxorubicin. HDAC activity, as measured by histone acetylation in peripheral blood mononuclear cells, was maximally inhibited at the abexinostat 30 mg/m 2 twice‐daily dose. Of the 17 participants who were evaluable for radiologic response, 1 patient had a partial response, 9 patients had stable disease, and 7 patients had progressive disease as their best response; and 8 patients completed ≥5 cycles. Three of those participants had stable disease as their most recent disease status when the current report was written. Four participants who continued on monotherapy remained in stable disease for a median of 9.8 weeks after completing doxorubicin. The most common toxicities were fatigue, thrombocytopenia, and anemia. No study‐related deaths were observed. CONCLUSIONS: The maximum tolerated dose for abexinostat was 45 mg/m 2 twice daily administered on days 1 through 5 when patients received doxorubicin 75 mg/m 2 on day 4 of a 3‐week cycle and G‐CSF support was mandated. Toxicities were manageable, and tumor responses were observed. Additional studies are needed to further define the specific contributions of HDAC inhibition in patients who receive doxorubicin for the treatment of metastatic sarcoma. Cancer 2015;121:1223–1230. © 2014 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.29175

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 62

Metadata

Authors
Choy, E., Flamand, Y., Balasubramanian, S., Butrynski, J. E., Harmon, D. C., George, S., Cote, G. M., Wagner, A. J., Morgan, J. A., Sirisawad, M., Mani, C., Hornicek, F. J., Duan, Z., & Demetri, G. D.
Venue
Cancer
Publisher
Wiley
Published
2014-12-23
Volume
121
Issue
8
Pages
1223-1230
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1513711324
Cited by
62
References
1
FWCI
1.83
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. https://app.cochat.ai/papers/10.1002/cncr.29175
The paper
Choy, E., Flamand, Y., Balasubramanian, S., Butrynski, J. E., Harmon, D. C., George, S., Cote, G. M., Wagner, A. J., Morgan, J. A., Sirisawad, M., Mani, C., Hornicek, F. J., Duan, Z., & Demetri, G. D. (2015). Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. Cancer. https://doi.org/10.1002/cncr.29175

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.